A study assessing the effect of a structured medication review on quality of life in patients with Parkinson's Disease

Parkinson’s Disease (PD) is a progressive disease resulting from degeneration of dopaminergic neurons within the substantia nigra. The golden standard for the management of PD is drug treatment to suppress (motor) symptoms. However, a considerable amount of PD patients do not fully benefit from their medical treatment due to complicated medication schedules, decreased adherence and progression of non-motor features. A potential intervention to enhance medication adherence is performing a structured medication review. As part of the ‘Medication Review in Parkinson’-study (NTR4500), this interim baseline-study aimed to evaluate the current study population of PD patients prior to the intervention of a structured medication review in a randomized controlled trial.